Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study

BACKGROUND: Radiotherapy may synergize with programmed cell death 1 (PD1)/PD1 ligand (PD-L1) blockade. The purpose of this study was to determine the recommended phase II dose, safety/tolerability, and preliminary efficacy of combining pembrolizumab, an anti-PD1 monoclonal antibody, with hypofractio...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Sahebjam, Solmaz, Forsyth, Peter A, Tran, Nam D, Arrington, John A, Macaulay, Robert, Etame, Arnold B, Walko, Christine M, Boyle, Theresa, Peguero, Edwin N, Jaglal, Michael, Mokhtari, Sepideh, Enderling, Heiko, Raghunand, Natarajan, Gatewood, Tyra, Long, Wendy, Dzierzeski, Jennifer L, Evernden, Brittany, Robinson, Timothy, Wicklund, Melissa C, Kim, Sungjune, Thompson, Zachary J, Chen, Dung-Tsa, Chinnaiyan, Prakash, Yu, Hsiang-Hsuan Michael
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Clinical Investigations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8041351/
https://ncbi.nlm.nih.gov/pubmed/33173935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa260
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi